WMSA
ELEV

Weiss Multi-Strategy Advisers’s Elevation Oncology ELEV Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio ELEV Stock Details ELEV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-14,342
Closed -$86K – 691
2021
Q4 		$86K Sell
14,342
-60
-0.4% -$414 ﹤0.01% 628
2021
Q3 		$112K Sell
14,402
-635
-4% -$6.87K ﹤0.01% 653
2021
Q2 		$204K Buy
+15,037
New +$186K ﹤0.01% 622

Other funds holding ELEV

ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Weiss Multi-Strategy Advisers's ELEV Position: Q1 2022 in Review

Weiss Multi-Strategy Advisers sold out of Elevation Oncology (ELEV) in Q1 2022, closing a stake of 14,342 shares — an estimated $86K sold.

Weiss Multi-Strategy Advisers first reported a position in ELEV in Q2 2021 and held it in 3 quarters. The position peaked at $204K in Q2 2021. 31 funds tracked by Wall St. Rank hold ELEV as of Q1 2022.

  • Weiss Multi-Strategy Advisers reported no remaining Elevation Oncology position as of Q1 2022 after selling out during the quarter.
  • Weiss Multi-Strategy Advisers sold 14,342 Elevation Oncology shares in Q1 2022, an estimated $86K.
  • Weiss Multi-Strategy Advisers first reported a position in Elevation Oncology in Q2 2021 and held it in 3 quarters.
  • Weiss Multi-Strategy Advisers's Elevation Oncology position peaked at $204K in Q2 2021.
  • 31 funds tracked by Wall St. Rank held Elevation Oncology as of Q1 2022.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q1 2022, filed 16 May 2022.